Back to search results

Study of Macupatide and Eloralintide for Weight Loss in Type 2 Diabetes

This study is looking for adults aged 18 to 75 who have obesity or are overweight, and also have type 2 diabetes. The goal is to see how much weight reduction can be achieved with two medications, macupatide and eloralintide, when given alone or together. You would need to have type 2 diabetes with an HbA1c (a measure of blood sugar over time) between 7.5% and 10.5%, and have been managing your diabetes with diet and exercise, metformin, or an SGLT2 inhibitor for at least 3 months. The main way we'll measure success is by looking at the change in body weight after 32 weeks. The study is currently unclear about its recruitment status and plans to enroll about 200 participants.

Study design
This interventional study plans to enroll about 200 participants. It will test macupatide and eloralintide, alone or in combination, along with placebos.
What's involved
Participation in this study will last about 48 weeks. The primary outcome, change in body weight, will be measured at baseline and Week 32.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 32, within the 48-week study duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215559

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Eli Lilly and Company
~200 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:MacupatideEloralintideMacupatide PlaceboEloralintide Placebo

At a glance

Recruiting sites
41 of 42 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight
Measured over Baseline, Week 32

Conditions

Obesity
Overweight
Diabetes Mellitus, Type 2

Explore related trials

ObesityOverweightType 2 Diabetes Mellitus

Where it's being run

42 sites across 13 states
Texas8
Australia8
Argentina6
Georgia5
Arizona3
Washington3
Virginia2
Puerto Rico2

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have type 2 diabetes
Have an HbA1c ≥7.5% to ≤10.5% at screening
Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
Diet and exercise
Stable dose of metformin
Sodium-glucose cotransporter-2 (SGLT2) inhibitor
Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
Have a BMI of 27 or greater at screening

Exclusion

Have any form of diabetes other than type 2 diabetes
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
Have any of the following cardiovascular conditions within 3 months prior to screening:
acute myocardial infarction
cerebrovascular accident (stroke)
unstable angina, or
hospitalization due to congestive heart failure
Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
basal or squamous cell skin cancer
in situ carcinomas of the cervix, or
in situ prostate cancer
Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
amylin RA
dual amylin and calcitonin RA
glucagon-like peptide-1 receptor (GLP-1) RA
glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
GLP-1/glucagon (GCG) RAs, or
GIP/GLP-1/GCG RAs
Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

What this trial measures

  • Percent Change from Baseline in Body WeightBaseline, Week 32